Atossa Genetics Inc. (NASDAQ:ATOS) has garnered a consensus recommendation of “Hold” from five brokerages monitoring the company, according to Marketbeat.com. The analysis reveals a divided perspective among analysts, with two recommending a sell, two advocating for a buy, and one offering a strong buy rating. The average price target for the stock over the next twelve months stands at approximately $6.33.
Several analysts have recently weighed in on Atossa Genetics. On October 8, 2023, Weiss Ratings reaffirmed a “sell (d-)” rating for the company. Shortly thereafter, on October 13, Zacks Research downgraded Atossa Genetics from a “hold” to a “strong sell” rating. In contrast, Ascendiant Capital Markets raised their price target for the stock from $7.75 to $8.00, aligning with a “buy” rating in a report released on December 8.
Current Market Performance
As of Monday, shares of Atossa Genetics traded at $0.59, reflecting a decline of 5.1%. The stock’s recent performance indicates a fifty-day simple moving average of $0.78 and a two-hundred-day average of $0.83. The company’s market capitalization is currently around $76.21 million, with a price-to-earnings ratio of -2.46 and a beta of 0.95. Over the past year, Atossa Genetics has seen its stock fluctuate, hitting a low of $0.55 and a high of $1.29.
The latest quarterly earnings report, released on November 12, 2023, matched analysts’ expectations, with the company reporting earnings per share of ($0.07). Looking ahead, analysts predict that Atossa Genetics will post a yearly earnings per share of (-0.22).
About Atossa Genetics
Based in Seattle, Washington, Atossa Genetics Inc. is a clinical-stage biotechnology company dedicated to developing therapeutics and diagnostic products for breast cancer and related conditions. The company’s mission focuses on delivering targeted and minimally invasive solutions for early detection, treatment, and prevention of breast malignancies in women at risk or diagnosed with the disease.
Atossa’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen aimed at treating and preventing estrogen receptor-positive breast cancers. This is particularly relevant for patients diagnosed with ductal carcinoma in situ or those deemed at high risk of recurrence.
For those interested in tracking Atossa Genetics, Marketbeat.com offers a daily email newsletter summarizing the latest news and analysts’ ratings for the company and its peers.
